Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,017.70 -7.58 (-0.74%)
Streaming Delayed Price Updated: 10:43 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
News headline image
Which S&P500 stocks are moving before the opening bell on Tuesday? ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
News headline image
AI Is Driving Healthtech Investments To New Heights, But Watch These 3 Overlooked Areas ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms ↗
The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid... 
Via Stocktwits
News headline image
Eli Lilly's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might ↗
The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well. 
Via The Motley Fool
News headline image
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
5 Dividend Stocks to Hold for the Next 20 Years ↗
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
News headline image
Biotech Is Booming, and This Undervalued REIT Stands to Gain ↗
Via The Motley Fool
News headline image
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China ↗
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market. 
Via Benzinga
Topics Law Enforcement Supply Chain
News headline image
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs ↗
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon. 
Via Benzinga
Topics Economy Government World Trade
News headline image
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel ↗
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
News headline image
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster ↗
 
Via Benzinga
News headline image
The 3 Things That Matter for Eli Lilly Now ↗
Via The Motley Fool
News headline image
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound ↗
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs ↗
 
Via Benzinga
News headline image
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
News headline image
2 Vanguard ETFs That Can Turn $400 per Month Into Over $1.7 Million ↗
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors. 
Via The Motley Fool
Topics ETFs
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗
Via The Motley Fool
News headline image
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results ↗
Via The Motley Fool
News headline image
5 Monster Stocks to Hold for the Next 25 Years ↗
Buy-and-hold investing only works if you choose the right companies. Here are some potential examples. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters ↗
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
Via The Motley Fool
News headline image
Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. ↗
Via The Motley Fool
Topics Government World Trade
News headline image
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? ↗
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
Top S&P500 movers in Thursday's session ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.